Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER plus ) breast cancer: Relevance to palliative treatment

被引：0
|
作者：
Symmans, William Fraser
Andreopoulou, Eleni
Booser, Daniel J.
Hatzis, Christos
Wallace, Michael J.
Zhang, Ya
Gong, Yun
Ignatiadis, Michail
Sotiriou, Christos
Andre, Fabrice
Peintinger, Florentina
Regitnig, Peter
Marth, Christian
Desmedt, Christine
Loi, Sherene
Moulder, Stacy L.
Hortobagyi, Gabriel N.
Pusztai, Lajos
Valero, Vicente
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Nuvera Biosci Inc, Woburn, MA USA
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] Inst Gustave Roussy, Villejuif, France
[5] Graz Univ, Graz, Austria
[6] Med Univ Innsbruck, A-6020 Innsbruck, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
515
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER plus ) breast cancer.
    Ebbinghaus, S.
    Blum, J. L.
    Cortes, J.
    Rugo, H. S.
    Swanton, C.
    Eaton, L.
    Song, Y.
    Zhang, T.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Hyperthermia plus radiotherapy in Estrogen receptor positive (ER plus ) breast cancer; before or after?
    Joveini, Zahra
    Behrouzkia, Zhaleh
    Aghdam, Reza Zohdi
    CANCER RESEARCH, 2017, 77 (22)
  • [23] Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S7 - S8
  • [24] Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S7 - S8
  • [25] Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer
    Agrawal, Anil
    Ziolkowski, Piotr
    Grzebieniak, Zygmunt
    Jelen, Michal
    Bobinski, Piotr
    Agrawal, Siddarth
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (08) : 550 - 555
  • [26] Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
    Aggelis, Vassilis
    Johnston, Stephen R. D.
    DRUGS, 2019, 79 (17) : 1849 - 1866
  • [27] Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer
    Kaklamani, Virginia G.
    Gradishar, William J.
    ONCOLOGIST, 2017, 22 (05): : 507 - 517
  • [28] Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
    Vassilis Aggelis
    Stephen R. D. Johnston
    Drugs, 2019, 79 : 1849 - 1866
  • [29] Estrogen receptor-positive (ER plus ) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes
    Levin, Maren K.
    Wang, Kai
    Yelensky, Roman
    Cao, Ying
    Ramos, Corinne
    Hoke, Glenn D.
    Pippen, John E.
    Blum, Joanne Lorraine
    Brooks, Barry Don
    Palmer, Gary A.
    Palma, Norma Alonzo
    Balasubramanian, Sohail
    Ross, Jeffrey S.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Overcoming tamoxifen resistance and inhibiting metastatic recurrence in estrogen receptor-positive breast cancer
    Ersan, Pelin Gulizar
    Saatci, Ozge
    Tarman, Oguzhan
    Mishra, Rasmi
    Belder, Nevin
    Tokat, Unal Metin
    Riazalhosseini, Yasser
    Sahin, Ozgur
    CANCER RESEARCH, 2019, 79 (13)
12345